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2007;118:295–303.Letters to the Editorhe Role of Omega-3 Fatty
cids in Primary Prevention of
oronary Artery Disease and in
trial Fibrillation Is Controversial
e read with interest a recent review article on the cardiovascular
ffects of omega-3 fatty acids (-3 PUFA) by Lavie et al. (1) and
ish to highlight some of the controversial issues in this review. In
elation to the role of -3 PUFA in primary prevention of
oronary artery disease (CAD), the authors quote 3 studies—the
ART (Diet And Reinfarction Trial) (2), GISSI Prevenzione
Gruppo Italiano per lo Studio della Sopravvivenza nell’ Infarto
iocardico–Prevenzione) study (3), and JELIS (Japan EPA Lipid
ntervention Study) (4)—as supportive evidence for a beneficial
ffect. As discussed further in the same review, the DART and
ISSI Prevenzione studies are secondary prevention studies, and
n the JELIS—which included 14,981 subjects in primary preven-
ion and 3,664 subjects in secondary prevention—major coronary
vents were indeed significantly reduced in the -3 PUFA-treated
ubjects. However, when the groups with and without previous
AD (i.e., primary and secondary prevention cohorts) were
ndividually analyzed, there was no benefit in the primary preven-
ion group. Therefore, the 3 studies quoted by the authors do not
end any supportive evidence to the claim that -3 PUFA are
seful in primary prevention of CAD.
In addition, the authors claim that the most significant antiar-
hythmic effects of -3 PUFA are noted in studies on atrial
brillation (AF) and quote 2 interventional studies (5,6) in
ddition to 1 observational study (7). To our knowledge, there has
een only 1 interventional study published on the effect of -3
UFA on AF after coronary artery bypass graft surgery. This study
y Calò et al. (5) is a relatively small open-label study in 160
atients who received 2 g/day of -3 PUFA for 5 days before
oronary artery bypass surgery. The second study referred to by the
uthors (6) is in fact a systematic review of studies that have
valuated all interventions that might be of benefit in reducing AF
fter coronary artery bypass graft surgery.
We wish to highlight that there were 2 large epidemiological
tudies—the Rotterdam Study (8) quoted by the authors and thessociation between the risk of developing AF and dietary fish
ntake.
Of note, the study by Mozaffarian et al. (7) exclusively looked at
ubjects 65 years of age and could not be extrapolated to the
ntire population at risk of AF, which would include both young
often lone AF) and old (often with underlying structural heart
isease).
The authors have failed to indicate that a recent systematic
eview by Leo´n et al. (10) and a systematic review of the 3 large
tudies on implantable cardioverter-defibrillator population (11)
ave reported no benefit with -3 PUFA therapy on cardiac
rrhythmias. Hence, we believe that the role of -3 PUFA on
rimary prevention of CAD and AF are far from clear as this
eview seems to suggest.
Palaniappan Saravanan, MD
eil C. Davidson, MD
Cardiovascular Research Group
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eply
e thank Drs. Saravanan and Davidson for their insightful
omments regarding details of our omega-3 polyunsaturated fatty
cid (-3 PUFA) review and appreciate the opportunity to clarify
ssues that might have been prone to misinterpretation (1). We did
ot imply that the DART (Diet and Reinfarction) study (2),
ISSI Prevenzione (Gruppo Italiano per lo Studio della Soprav-
ivenza nell’ Infarto Miocardico–Prevenzione) study (3) and
ELIS study (Japan EPA Lipid Intervention Study) (4) were trials
ith a uniform population but in fact stated that they represent an
ggregate of evidence toward both secondary and primary preven-
ion. They correctly point out that the DART study (2) and the
ISSI-Prevenzione study (3) are secondary prevention studies
ith a significant -3 PUFA benefit in over 13,000 post-
yocardial infarction patients. However, even in secondary pre-
ention, not all studies have demonstrated benefit (1). The JELIS
rial (4), in contrast, tested the effects of eicosapentaenoic acid
EPA) in mostly a primary prevention cohort (n  14,981 with
ypercholesterolemia treated with statins). Here, the effect size was
ssentially identical (18% vs. 19%) to that seen in the secondary
revention group (n  3,664), but the 5-year event rate was nearly
-fold higher in the secondary prevention group (12% vs.  2%).
s Drs. Saravanan and Davidson correctly point out, in the entire
rimary prevention group, the benefits of EPA were not quite
tatistically significant (hazard ratio: 0.82; 95% confidence interval:
.63 to 1.06; p  0.13). In a subgroup of JELIS primary
revention patients (5), those with triglycerides 150 mg/dl and
igh-density lipoprotein cholesterol 40 mg/dl had event rates
hat were nearly 2-fold higher than those without this lipid
attern. In patients with this high-risk lipid combination, EPA
educed major cardiac event rates by 53% (p  0.043). Along with
he notable epidemiological data, we believe that the overall
vidence suggests benefits of -3 PUFA at least in high-risk risk
rimary prevention patients as well as in those needing secondary
revention of coronary heart disease.
We agree with Drs. Saravanan and Davidson that our single,
rief paragraph on the impact of -3 PUFA in atrial fibrillation
AF) was oversimplified (in an effort to make a lengthy review
ore concise). Although the observational study by Mozaffarian
t al. (6) suggested that high fish intake was associated with a 30%
eduction in AF over 12 years, the Rotterdam Study (7) found no
uch effect. Only 1 small randomized controlled study of 160
ost-bypass patients was performed to assess the benefits of -3UFA on the development of postoperative AF (8). The results of
his small study were remarkable in support of -3 PUFA,
ncluding 18.1% absolute risk reduction and 54.4% relative risk
eduction (or only 5.5 patients needed to be treated to prevent 1
pisode of AF). As this study points out and as we have discussed
lsewhere in more detail (9), these results compare favorably to the
esults of another large meta-analysis (58 studies including 8,565
articipants) (10), which examined the effects of amiodarone,
otalol, and beta blockers on post-bypass AF. In comparison, the
esults with -3 PUFA post-bypass seem to be similar or even
uperior to these other treatments to prevent AF. Clearly, larger
tudies are needed and some are underway (11) to assess the impact
f -3 PUFA in primary and secondary prevention of AF.
dditionally, higher doses of -3 PUFA (e.g., 2 to 5 g/day) need
o be studied in various cardiovascular diseases (CVD), including
F, and studies are needed to determine the relative benefits of
PA and docosahexaenoic acid (DHA) in CVD. It also is not
nown what impact DHA or EPA alone has in disease modifica-
ion, these areas being the subject of intense ongoing investigation.
Finally, we agree with Drs. Saravanan and Davidson that one
ould debate the details of the strengths and weaknesses of each
tudy. However, we believe the totality of the evidence suggests an
verall beneficial effect of -3 PUFA for CVD protection, a view
hat we are not alone in professing (12–14).
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